Agency Header

Drug Utilization Review Board

The Drug Utilization Review (DUR) Board is responsible for the establishment of standards and criteria for the prospective and retrospective DUR programs. The DUR Board is charged with making recommendations for educational interventions to prescribers and pharmacists to identify and reduce overuse, abuse, fraud, and inappropriate or medically unnecessary care. Health Information Designs, LLC (HID) assists the pharmacy program in conducting population-based educational interventions, approved by the DUR Board, for both medical prescribers and pharmacy providers.

Drugs or drug classes which are reviewed and found to be inappropriately utilized or have significant safety concerns are deemed candidates for prior authorization. These reviews are considered by the DUR Board and appropriate criteria for approval are determined by them, with input from medical and pharmacy providers, drug manufactures, and other experts


Members
Lester Labus, MD, Chair                 Kate Forman, PharmD
Kc Lovin, PA-C, Vice-Chair  Michael Lonsinger, PharmD
C.K. Babcock, PharmD  Ernest Miller, DO
Christopher Booth, PharmD  Mary Nemeth-Pyles, MSN, RN, CS
Scott Brown, RPh       Patrick Regan, PharmD
Myra Chiang, MD  Christopher Terpening, PharmD
Karen Fitzpatrick, MD  John Vanin, MD

Follow us on Facebook